Medtronic (NYSE: MDT) today announced the first results from the high cardiovascular risk cohort of its SPYRAL AFFIRM study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback